Dyne Therapeutics Inc. has reported its financial results for the second quarter of 2025. The company recorded a net loss of $110.9 million for the three months ended June 30, 2025, compared to a net loss of $65.1 million for the same period in 2024. The research and development (R&D) expenses increased to $99.2 million from $62.3 million year-over-year, while general and administrative (G&A) expenses rose to $16.6 million from $9.7 million in the previous year. As of June 30, 2025, Dyne's cash, cash equivalents, and marketable securities amounted to $683.9 million. Following a public offering in July 2025, the company expects this cash position, along with the net proceeds of approximately $215.2 million from the offering, to fund operations into the third quarter of 2027. This financial runway is anticipated to support the company's plans to obtain data from the registrational expansion cohorts of the ACHIEVE and DELIVER clinical trials, submit Biologics License Applications (BLAs) to the FDA for DYNE-251 and DYNE-101, and potentially launch DYNE-251 commercially in the U.S. if approved.